A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Maximum observed plasma concentration (Cmax)

Maximum observed plasma concentration (Cmax)

Time frame: Up to approximately 8 days after initial dose of study drug

Time to Maximum Observed Plasma Concentration (Tmax)

Time to maximum observed plasma concentration (Tmax).

Time frame: Up to approximately 8 days after initial dose of study drug

Apparent Terminal Phase Elimination Rate Constant (β or Beta)

Apparent terminal phase elimination rate constant (β or Beta).

Time frame: Up to approximately 8 days after initial dose of study drug

Terminal Phase Elimination Half-life (t1/2)

Terminal phase elimination half-life (t1/2)

Time frame: Up to approximately 8 days after initial dose of study drug

Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)

Area under the plasma concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUCt).

Time frame: Up to approximately 8 days after initial dose of study drug

AUC from time 0 to infinite time (AUC∞)

AUC from time 0 to infinite time (AUC∞)

Time frame: Up to approximately 8 days after initial dose of study drug